Related Experiment Video
Updated: Aug 23, 2026

Gas Chromatography-Mass Spectrometry Paired with Total Vaporization Solid-Phase Microextraction as a Forensic Tool
Published on: May 25, 2021
Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review
Michael McDonough1, Noel Kennedy, Anthony Glasper
1Addictions Directorate, South London and Maudsley Trust and Institute of Psychiatry, King's College, London SE5 8AF, UK. mmcdonough@stpatsmail.com
Aim:
To examine the clinical course of gamma-hydroxybutyrate (GHB) withdrawal and generate management guidelines.
Design:
Review and analysis of all published reports of GHB or GHB precursor withdrawal identified from electronic searches.
Findings:
In total, 38 cases of GHB (n = 28) or GHB precursor (n = 10) withdrawal were identified, 36 of which were from the US. A rapidly deteriorating course into delirium (53% of cases) was typical for heavily dependent users. Symptoms were broadly similar to alcohol withdrawal but often occurred earlier in usage with delirium being associated with severe dependence as determined by more frequent ingestion. High dose benzodiazepines were effective in pharmacological management of GHB withdrawal. In benzodiazepine refractory cases withdrawal responded to other sedative agents, mainly pentobarbital or chloral hydrate. No withdrawal seizures but one death was recorded.
Conclusions:
GHB withdrawal is potentially life threatening and requires vigorous clinical management, preferably as an inpatient for severe cases. A management algorithm is proposed.
More Related Videos
Related Concept Videos
Hypoglycemia and Glucagon
Diabetic Ketoacidosis l: Introduction
Hypoglycemia
Hyperosmolar Hyperglycemic State
Type I Diabetes III: Clinical Manifestations
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

